
1. Technology overview
Monitor Corporation was established in July 2018 by a research team at Seoul National University Bundang Hospital and is based in Seoul, South Korea. The company develops AI software for cancer screening on medical images, including lung CT and breast ultrasound.
MONCAD LCT, sold as LuCAS-PLUS in Korea, is an AI engine that detects and analyzes lung nodules on chest CT. It runs after imaging, links to hospital PACS, matches prior scans to track progression, and provides a dedicated viewer and simple diagnostic reports.
2. Highlighted features & specifications
- Nodule detection: AI engine detects and analyzes lung nodules on lung CT.
- Dedicated viewer: One-click navigation to each detected nodule.
- Prior scan matching: Automatically matches previous scans to simplify progression tracking.
- New finding highlight: Marks new findings so they are less likely to be overlooked.
- Multi-plane sync: Synchronizes images in three planes for follow-up.
- Always-on analysis: Analyzes scans automatically after imaging and produces simple reports.
3. Potential application
Radiology departments in Vietnam can use it as a second reader for chest CT in lung cancer screening. Health-check centers can apply automatic prior-scan matching to follow nodules over time.
4. Benefits
Reported sensitivity of 93.5% and specificity of 85.8% in an evaluation at a tertiary hospital in Korea. One-click navigation to detected nodules shortens reading. Automatic matching with prior scans highlights new findings that might be overlooked. Compatible with hospital PACS.
5. Market trends & opportunities
Lung cancer screening with low-dose CT increases reading workload for radiologists, which drives demand for AI-assisted nodule detection. Vietnamese hospitals expanding health-check and screening programs may look for such tools, though the vendor's page states availability only in South Korea.
6. Other information
Founded July 2018 at Seoul National University Bundang Hospital research team; Series B of KRW 7 billion in October 2024. MFDS Class III approval; designated an innovative medical device by MFDS in 2024. Partners include DoctorNet (Japan) and HealthHub.
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
RETAIL E-COMMERCE: AI AND REAL-TIME DATA ARE TRANSFORMING HOW RETAIL BUSINESSES OPERATE








































